Endocrine Testing Market Size, Outlook, Analysis Report, Regional Outlook with Forecast
Endocrine testing refers to medical
procedures used to measure hormonal levels in the body and diagnose
hormone-related disorders. The testing aids in detecting hormonal imbalances
that may lead to the development of certain chronic conditions. Fine-needle
aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance
imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI), and
venous sampling are commonly used to diagnose these disorders. The results of
the tests can help determine the progression of the disorder and monitor the
effects of the treatment given to the patient.
The increasing prevalence of endocrine
disorders, as well as advances in diagnostic technologies, are driving the Endocrine
Testing Market. Furthermore, the world's growing elderly population,
combined with rising awareness about early diagnosis and treatment, is expected
to drive market growth. Endocrine testing is the measurement of hormone levels
secreted by the endocrine glands as well as the diagnosis of disorders such as
obesity, diabetes, and thyroid disease.
The procedure for endocrine testing consists
of measuring the concentration of endocrine hormones in blood or urine. These
hormones are precise indicators of the presence of endocrine diseases, such as
hypo/hyperthyroidism, infertility, and so on. Pituitary glands, thyroid glands,
hypothalamus, pancreas, and adrenal glands are examples of endocrine glands
found in the body. Any imbalance in the hormones secreted by these glands
causes a specific disorder, so they are an important marker to diagnose a
specific condition.
Another major factor driving the growth of
the global endocrine testing market is the rising prevalence of obesity.
Obesity is frequently caused by hormonal imbalance, which requires endocrine
testing to treat. Obesity, which promotes a sedentary lifestyle and is usually
accompanied by excessive consumption of high-sugar foods, is also a
contributing factor to the rising incidence of diabetes.
The high costs of some advanced endocrine
testing technologies, on the other hand, are a major restraint on the global
endocrine testing market. Despite their utility in the diagnosis of a variety
of diseases, endocrine testing remains out of reach for a large portion of the
developing world's population, and this is unlikely to change in the near
future. The lack of general healthcare awareness in underdeveloped regions has
also stifled the growth of the global endocrine testing market.
Comments
Post a Comment